 |
인쇄하기
취소
|
Celgene Korea to negotiate Revlimid price
The National Health Insurance Corporation (NHIC) will decide Celgene’s cancer drug Revlimid to be put on the positive list and how much it will cost through negotiations with Celgene Korea, according to pharmaceutical sources.
The Health Insurance Review and Assessment Service (HIRA said last Sunday that Revlimid is eligible for the list
Celgene Korea had been in desperate negotiations ...
The Health Insurance Review and Assessment Service (HIRA said last Sunday that Revlimid is eligible for the list
Celgene Korea had been in desperate negotiations ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.